Chokri Ben Lamine: Strategic Decision Making in Hematology under Competing Risks
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Game theory in Hematology equals strategic decision-making under competing risks (disease vs toxicity vs cost vs time).
Core idea: optimize outcome when multiple players (tumor, host, physician, system) interact․
AML induction vs wait
- aggressive disease equals ‘move early’ (dominant strategy)
- frail pt equals delay/low-intensity leads to minimize loss (minimax)․
MRD-guided decisions
- MRD positive leads to escalate (allo-SCT)
- MRD negative leads to de-escalate
- dynamic strategy equals sequential game․
CAR-T vs bispecific vs SCT
- competing strategies with different payoffs (CR, toxicity, durability)
- choose based on patient fitness plus tumor biology leads to expected utility maximization․
GVHD vs GVL balance
- immunosuppression decrease GVHD but increase relapse
- optimal point equals Nash equilibrium between immune control and toxicity․
Anticoagulation in cancer thrombosis
- bleeding risk vs clot risk
- adjust dose/timing leads to risk-dominant strategy․
Transfusion thresholds (PBM)
- liberal vs restrictive
- restrictive often ‘dominant strategy’ leads to same outcomes, fewer risks․
Antibiotic use in FN
- overuse leads to resistance
- underuse leads to mortality
- stewardship equals repeated game with system-level payoff․
Clonal evolution (AML/CLL/MM)
- tumor adapts to therapy equals ‘evolutionary game’
- combination/sequencing prevents resistant clone dominance․
Resource allocation (ICU beds, CAR-T slots)
- prioritize pts with highest benefit probability
- utility plus fairness balance․
One-liner
Hematology decisions equals multi-step strategic games leads to best outcomes when timing, sequencing, and risk trade-offs are optimized.”
Stay updated with Hemostasis Today.
-
Jun 29, 2026, 06:48Christina Pohlman: Anticoagulants and Bone Health – APS Awareness Month Day 23
-
Jun 29, 2026, 06:33Andreas Calatzis: Can Fibrinolysis Sensitivity Be Claimed Without a Reference Standard
-
Jun 29, 2026, 06:25Aliaa Albadri: When a Hair Wash Leads to a Stroke Workup
-
Jun 29, 2026, 06:22Tehreen Parveen: Historical Milestone in Drug Discovery – The Discovery of Aspirin
-
Jun 29, 2026, 06:16Muhammad Sufyan: Deep Vein Thrombosis – Recognizing the Warning Signs
-
Jun 29, 2026, 05:33Janak Sadhu: Uniting for The Stroke-Free Mehsana Initiative
-
Jun 29, 2026, 05:20Deepti Sachan: A Global Exchange Shaping the Future of Transfusion Medicine at ISBT 2026
-
Jun 29, 2026, 04:50Scott Cameron: ACC/AHA Guidance on Acute Pulmonary Embolism Management
-
Jun 29, 2026, 03:10Aryabhatta Sadhu: ABO and Rh Incompatibility In Stem Cell Transplantation